Never miss a story

Get subscribed to our newsletter


×
Elizabeth Holmes, founder and CEO of Theranos, speaks at the Fortune Global Forum in San Francisco, Nov. 2, 2015. Federal prosecutors said Friday they have indicted Holmes on criminal fraud charges for allegedly defrauding investors, doctors and patients. VOA

Federal prosecutors have indicted Elizabeth Holmes on criminal fraud charges for allegedly defrauding investors, doctors and the public as the head of the once-heralded blood-testing startup Theranos. Federal prosecutors also brought charges against the company’s former second-in-command.

Holmes, who was once considered a wunderkind of Silicon Valley, and her former Chief Operating Officer Ramesh Balwani, are charged with two counts conspiracy to commit wire fraud and nine counts of wire fraud, the U.S. Attorney’s Office for the Northern District of California said late Friday. If convicted, they could face prison sentences that would keep them behind bars for the rest of their lives, and total fines of $2.75 million each.


Technology a fraud

Prosecutors allege that Holmes and Balwani deliberately misled investors, policymakers and the public about the accuracy of Theranos’ blood-testing technologies. Holmes, 34, founded Theranos in Palo Alto, California, in 2003, pitching its technology as a cheaper way to run dozens of blood tests. Once considered the nation’s youngest female billionaire, Holmes said she was inspired to start the company in response to her fear of needles.

But an investigation by The Wall Street Journal two years ago found that Theranos’ technology was a fraud, and that the company was using routine blood-testing equipment for the vast majority of its tests. The story raised concerns about the accuracy of Theranos’ blood testing technology, which put patients at risk of having conditions either misdiagnosed or ignored.

“CEO Elizabeth Holmes and COO Sunny Balwani not only defrauded investors, but also consumers who trusted and relied upon their allegedly-revolutionary blood-testing technology,” Acting U.S. Attorney Alex Tse said in a statement.


Elizabeth Holmes, flickr

SEC charges

The Securities and Exchange Commission brought civil fraud charges against Holmes and Balwani three months ago. Holmes settled with the SEC, agreeing to pay $500,000 in fines and penalties. Balwani, 53, is fighting the charges.

As the charges were announced Friday, Theranos said Holmes would step down as CEO of the company and its general counsel, David Taylor, would become the company’s next CEO. Theranos laid off most of its staff earlier this year and is widely expected to file for bankruptcy. Holmes remains the company’s chairman.

Also read:Two Indian-Americans among Forbes America 50 successful women

The company did not immediately respond to a message seeking comment on Friday’s indictments. (VOA)


Popular

Kishu Inu and Dogelon Mars are some of the more popular canine coins in recent months. Their popularity is demonstrated by the vast amount of trading volume that these cryptocurrencies receive.

At the time of writing, Kishu Inu has a trading volume exceeding $10 million and Dogelon Mars has an even larger trading volume that surpasses $30 million.

Keep Reading Show less

HUH Token

It’s here, and it appears that there ain’t nothin’ or no one stopping the skyrocketing force of HUH Token and the release of the long-awaited White Paper is finally here and we’re living for it.

It’s also great to note that Shiba Inu made a triumphant crypto market return this week and the reign of the dog continues though with HUH Token’s White Paper release it could see the ‘Utimeme’ token break out of the atmosphere on its December 6th launch and surpass Shiba Inu for altcoin supremacy.

Keep Reading Show less

HUH Token

HUH Token has been on the lips of crypto lovers for some time now and the much-anticipated White Paper release is here, right now, today!

Not only this but Shiba Inu’s mastery of the altcoin world could be coming to an end on HUH Token’s December 6th release if the aims, goals and technology in the White Paper are anything to go by.

Keep reading... Show less